ProtoKinetix Accepts Director’s Resignation

ST. MARYS, W.Va.--()--ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) (“ProtoKinetix” or the “Company”) announces that it has received and accepted the resignation of Mr. Peter K. Jensen as a Director of the Company effective as of April 30, 2015. Mr. Jensen’s resignation was due to personal reasons, and not as the result of any disagreement with the Company practices or policies.

Effective April 30, 2015, the Board of Directors of the Company appointed Mr. Jensen to the Company’s Business and Scientific Advisory Board to provide ongoing consulting services to the Company.

“We are pleased that Peter will continue to provide his extraordinary biotechnology and business expertise as a member of the Business and Scientific Advisory Board,” said Clarence Smith, ProtoKinetix President, Chief Executive Officer and Chairman.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhances therapeutic results and reduces the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

Cautionary Statement Regarding Forward-Looking Information

Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law, including statements regarding the Company's intention to license the Patent rights to third parties and the potential treatments for which the Company's AAGPTM may be applied. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. More detailed information about potential factors that could affect financial results is included in the documents filed by the Company from time to time with the United States Securities Commission and with securities regulatory authorities in Canadian on SEDAR.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Contacts

ProtoKinetix, Incorporated
Clarence E. Smith, President & Chief Executive Officer
304-299-5070
csmith@protokinetix.com

Release Summary

ProtoKineix Accepts Director's Resignation

Contacts

ProtoKinetix, Incorporated
Clarence E. Smith, President & Chief Executive Officer
304-299-5070
csmith@protokinetix.com